UNTIL 1972, the only clinical trial in which immunotherapy had beeii claimed to be beneficial in the treatment of any form of malignant disease in man was that of Mathe' et al. (1969) (Powles et al., 1973) . All the chemotherapy, both during induction and d-Liring remission, was administered at St. Bartholomew's Hospital, London (Bart's) but those patients who were allocated to receive immunotherapy were in addition seen regularly at the Roi-al Marsden Hospital, where all the immunotherapy was administered. By August 1972, these series were all quite small, but the duration of first remission and of survival were, overall, somewhat better in the immunotherapy group than in the controls. The studies were numbered two dozen patients, and when Studies 2, 3 and 4a, all of which involved a similar form of immunotherapy, were pooled, the apparent effects of immunotherapy on duration of first remission and on survival were moderately significant statistically (P<0.05). Although the immunotherapy was all administered at the Royal Marsden, this pool of Studies 2, 3 and 4a has come to be known as "the Bart's trial", and the chemotherapeutic regime used in Study 3 has come to be known as "Bart's 3 chemotherapy".
The encouraging preliminary results from the Bart's trial indicated the need for a randomised trial duplicating their study on a larger scale, and we now report the results of the trial organized by the Medical Research Council's (MRC) Working Party on Leukaemia in Adults which began in January 1973 with this purpose.
For practical reasons, the MRC trial was confined to Hammersmith Hospital and Oxford until 1974. In 1974, 6 hospitals in the Birmingham region joined the trial. At Manchester Royal Infirmary the research team had already had some experience with immunotherapy (Freeman et al., 1973 ) and wanted to randomise their patients between immunotherapy alone and chemotherapy plus immunotherapy to discover whether chemotherapy during remission was ofvalue to patients receiving immunotherapy. The Manchester part of the MRC study will be reported separately.
At Birmingham, Hammersmith and Oxford 148 patients presented; 77 of these achieved complete remission (520 %) and 71 of these were randomised between chemotherapy and chemotherapy plus immunotherapy.
PATIENTS AND METHODS
From 1st January, 1973 to 30th June, 1976 patients who had entered complete remission were allocated at random to receive maintenance therapy, either with chemotherapy alone (C, 24 patients) or with immunotherapy as well as the same chemotherapy (C+I, 47 patients). The follow-up is complete to 1st July 1977.
The chemotherapy schedules for induction and maintenance therapy were identical with those described by Powles et al. (1973) except that doxorubicin was occasionally substituted for daunorubicin, at half the dosage, to reduce the risk of cardiotoxicity. For details of the induction chemotherapy with the 5-day course of daunorubicin and cytosine arabinoside repeated at 10-day intervals, and of the monthly maintenance chemotherapy courses of the same drugs, alternating with thioguanine and cytosine arabinoside, see Powles et al. (1973) .
The (C+I) was made to alternate patients at the time of first presentation, before remission had been induced. In the MRC trial, the allocation was made randomly, at the time when the patient was first recorded as having entered a state of complete remission. The randomization procedure was adjusted so that twice as many patients would be allocated to receive (C+I) as C.
(2) In the Bart's trial, immunotherapy was begun "whenever possible, just before complete remission, at a time when the marrow was hypoplastic" (Powles et al., 1973) . This was possible because the patients had already been allocated to receive immunotherapy. In the MRC trial, randomization was deferred until complete remission was established, as shown by the regeneration in the marrow of normal haemopoietic cells as well as the reduction of blast cells below 5%.
After the first marrow sample considered to show complete remission, one further "consolidation" course of chemotherapy was given before starting immunotherapy. Thus, immunotherapy was begun 1 to 4 weeks later in the MRC trial patients than in the Bart's trial patients.
(3) In the MRC trial, the marrow was examined on the first day of every monthly course of maintenance chemotherapy, with the object of detecting relapse as early as possible. Blast-cell counts above 5% were considered to indicate relapse, but to allow for variation between different sites in the marrow, and for observer variability, a single sample of marrow showing 5-10% of blasts was not accepted as indicating relapse unless blast cells were present in the peripheral blood film at the same time. If they were not, a second marrow sample was taken 4 weeks later, and a blast-cell count above 5% was then accepted as indicating relapse. In the Bart's trial, marrow examinations were not made routinely during remission, being performed only when indicated by the peripheral blood and clinical findings.
(4) In the MRC trial, in accordance with the practice in earlier trials, patients aged 20 years and over who had undifferentiated leukaemia were eligible for entry, whereas in the Bart's trial they were deliberately excluded, entry being restricted to patients with leukaemia showing definite myeloid (granulocytic and/or monocytic) differentiation.
(5) Finally, in the Bart's trial, when patients relapsed, "the initial induction treatment with daunorubicin and cytosine arabinoside was repeated whenever possible". In the MRC trial, participants were encouraged to do this, but were free to use more intensive treatment for patients who relapsed within 120 days or for a second time.
COMPLICATIONS OF IMMUNOTHERAPY
In general, immunotherapy was well tolerated; however, severe reactions occurred in a few cases. The sites of the BCG inoculations were sometimes slow to heal and, when persistently discharing ulceration occurred, inoculations of BCG were discontinued until the ulcers had healed. In 2 cases in which the BCG inoculation sites healed normally, the sites of the blastcell injections became inflamed and ulcerated, the patients became febrile, and BCG organisms were recovered from the ulcer. These patients were considered to have developed systemic BCG disease and were successfully treated with antituberculosis drugs. Rarely, patients complained of generalised muscle aching and weakness during the 24 h following immunotherapy, and most patients complained of transient pain at the inoculation sites.
In 3 immunotherapy patients temporary iritis was reported, though no explicit search for this condition was organised.
STATISTICAL METHODS These are as described by Peto et al. (1976; and consist of KaplanMeier life tables and logrank P values*. For the latter, exact variance calculations were performed (ibid., Statistical Note 7) and continuity corrections were not used (ibid, p. 38). (1) Duration of complete remission (I.e. time from definite remission to first relapse or, for 2 patients who died while still in their first remission, to death.)
There were no significant differences in the duration of first remission between patients of different ages or patients from different centres (Oxford, Hammersmith or Birmingham region) ( Table I) . Although the immunotherapy patients fared slightly better (Fig. 1) this difference was not statistically significant (Table I ) (whether tested directly or after retrospective stratification for centre.) "Retrospec- (Peto et al., 1976; implies that, in making the overall treatment comparison, patients at one centre are not assumed to be comparable with patients elsewhere.) The ratio of the relapse rate among immunotherapy patients to that among the controls was 074, but because the trial is not large, the 95% confidence interval for this ratio is rather wide (,.'0O45-1-20) and our data are thus consistent both with no effect whatsoever for immunotherapy and with a halving of the relapse rate by immunotherapy.
(2) Duration of survival from the date of relapse
The median survial after relapse had been diagnosed was only 124 days (18 weeks) and it tended to be shorter in the Birmingham area (14 weeks) than at Hammersmith and Oxford (22 weeks).
After relapse, the immunotherapy+ chemotherapy patients (Fig. 2) unreliable* because medians are derived from only a single point on the whole survival curve. It is, therefore, usually preferable to use a logrank test to see whether, taking the entire shapes of the two curves into consideration, the differences between the two curves can be plausibly attributed solely to chance. Unfortunately, as with remission duration, the results are equivocal. There is no statistically significant difference in survival after relapse (chi-square on one degree of freedom 2, one-tailed P=008) yet the data are consistent not only with no effect but also with at least a halving of the death rate among relapsed patients (observed death rate ratio-0*68, 95% confidence interval -0-40-1.15).
(3) Survival from randomization (i.e.) from the onset of remission)
As might be expected, the relationship of treatment to overall survival is similar to that with remission duration (Fig. 3 and Table III ). Again, the data are consistent both with a halving of the death rate and with no effect whatever. (The observed death rate ratio was 067, with 95% confidence interval -'0O39-1-14.) DISCUSSION The present trial was started in 1973, shortly after an unpublished statistical analysis of the Bart's immunotherapy trial suggested that the duration of remission was significantly longer if, during remission, the patients received weekly immunotherapy in addition to monthly courses of chemotherapy, instead of the same chemotherapy alone. Analysis of the Bart's results one year later (Powles et at., 1973) suggested that, in addition to the prolongation of the first remission, the duration of survival after the first relapse and the overall survival were also superior in the group of patients who had received immunotherapy.
Further follow-up of the original Bart's trial (Powles et al., 1977) has shown that the statistical significance of the effect on first remission which they originally reported (Powles et al., 1973) no longer exists. Now that more complete information is available for all their patients, it appears that the effect reported earlier on the duration of first remission could have been a temporary artefact of chance, and all but one patient in their original immunotherapy group had relapsed by the end of 1976.
In our data, the immunotherapytreated group has had slightly longer durations, both of first remission and of survival after first relapse. However, both * For example, although the discrepancy of 8 weeks between these two medians looks promising, consider the medians we would have obtained if just one extra immunotherapy patient had relapsed. If this hypothetical patient had died 6 months after his relapse, the present medians would be unchanged, but if he had died four months after his relapse the discrepancy between the medians of the two treatment groups would be reduced to 4 weeks. these differences (and the difference with respect to total survival) are easily compatible with (a) immunotherapy being completely without benefit, and (b) immunotherapy halving the relapse rate, the death rate among relapsed patients, or both.
A larger trial would have been much more informative, but this was not achieved for the reasons already described; but, it should be remembered, our trial is larger than any other randomized trial of immunotherapy for AML yet reported. To obtain independent confirmation or refutation of the original Bart's results, we must therefore look to other series of patients. Two questions need answering: Does immunotherapy prolong first remission? and does immunotherapy prolong survival after relapse? First Remission
At a meeting at the National Cancer Institute (NCI, 1977) All other centres participating in the 6th AML trial during the period of intake to the present trial used, in one arm or other, the same chemotherapy and criteria of 9 4-) 0 -< AA remission as in the present trial. All except Manchester used no immunotherapy and, among the 40 such patients who achieved remission, first remissions were actually slightly longer than among either group in our randomized trial. Conversely, 10 patients at Manchester received immunotherapy as well as this chemotherapy, and their first remissions were slightly shorter than in our randomized trial. Finally, 41 patients remitting at Bart's during this period (after closure of their trial) received various different forms of chemotherapy and various different forms of immunotherapy, and their first remissions were also slightly shorter than among either group in our randomized trial. These three concurrent comparisons are all uncertain, because the treatments were not allocated by randomization, but none suggests that immunotherapy prolongs first remissions.
Survival After Relapse
Here, the 5 other randomized studies and the 3 concurrent comparisons all indicate, as was originally suggested by Freeman et al. (1973) that immunotherapy does prolong survival after relapse. In all 6 randomized trials (NCI, 1977) survival after relapse was better for immunotherapy patients, and in 3 of these the differences were apparently statistically significant. (However, the detailed data from one of these 3 trials have been tabulated by Whittaker and Slater (1977) and reanalysis of the tabulated data indicates that although a difference certainly exists, it is not statistically significant.)
In the MRC 6th chemotherapy trial, 28 of the (already mentioned) 40 patients treated according to the "Bart's 3" protocol relapsed, and these 28 then died more quickly after relapse than either of the two groups in the present randomized trial. By contrast, both the group of 10 C+1 patients who relapsed at Manchester, and the group of 31 C+I patients who presented at Bart's after closure of their trial and relapsed before 1977, lived longer after relapse than did either randomized group in the present trial. This reinforces the suggestion that immunotherapy can prolong survival after relapse, but again the possible biases inherent in such nonrandomized comparisons should be emphasized.
Other Reports of the Present Trial
At the NCI review meeting in October 1976 (NCI, 1977) our results to the end of September 1976 were presented. The present paper reports our results 9 months later, when 16 further relapses and deaths have occurred (6 among C-only patients and 10 among C+I patients, because twothirds of our patients were allocated to receive C+J). The present uncertain results are almost identical with the results presented then. However, at the MRC annual review meeting, a significant effect of immunotherapy in prolonging survival after relapse was reported from this trial. This was because all 6 of the Conly events occurred before 1 January 1977, while only 2 of the 10 C+I events did so. In small trials, quite rapid changes can always occur, and because 19 patients remain alive (9 in first remission) further fluctuation is still possible but perhaps unlikely.
CONCLUSION
It seems probable, though not certain, that immunotherapy can prolong survival after relapse, and it is possible that it can slightly extend first remissions. The mechanism in either case remains obscure, and comparisons with successful immunotherapy in experimental animals are not necessarily relevant. If our "immunotherapy" really does have some effect, elucidation of its mechanism might lead to improvement in its efficacy. It is, however, not yet clear that future efforts to improve survival in AML should chiefly be directed to improving immunotherapy, and we have not included immunotherapy in the current (7th) MRC AML trial.
Several laboratory tests, including studies of the immunological responses of the patients receiving immunotherapy in the trial reported here, have been carried out, and several of the blast-cell preparations used for immunization proved to be immunogenically "inert" (personal communication: Dr I. C. M. MacLennan, Dr D. Gale, Dr R. Harris, Dr G. M. Taylor). It remains possible, therefore, that other forms of immunotherapy may be more effective. In experimental animals immunotherapy is effective only when the number of residual tumour cells is very small.
Possibly our immunotherapy was begun too soon or too late to be maximally effective. The Manchester group have suggested more intensive consolidation therapy before randomizing between immunotherapy and no other maintenance treatment, and they are now carrying out a trial so designed. Note added in proof.-By 1 November 1977, all patients had been followed for 22 or more months, and on further statistical analysis the 3 treatment chi-squares (retrospectively stratified for centre) became 1P53 (first remission), 1-97 (survival after relapse) and 2-61 (overall survival). None of the explanatory variables listed in the Appendix (no. of courses, sex, age, morphology, centre or WBC) were significantly related to any measure of outcome, nor did retrospective stratification for any of them materially affect the relationships of treatment with outcome. (However, patients with only 3, 4 or 5 courses of tratment during the first 12 weeks after diagnosis did live slightly longer than those with 6, 7 or 8 courses, and the apparent effect of immunotherapy was somewhat greater among the latter than among the former patients.) Because the Bart's trial excluded patients with undifferentiated leukaemia, we finally re-analysed our data excluding our 9 such patients; their prognosis was slightly worse than average, and no material change in any of our 3 treatment comparisons followed their exclusion. 
